Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735

/PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...

Related Keywords

,Drug Administration ,Twitter ,Ligand Pharmaceuticals Incorporated ,Prnewswire Viking Therapeutics Inc ,Therapeutics Inc ,Nasdaq ,Placebo Adjusted Mean Weight Loss ,From Baseline ,Observed After ,Obesity Planned ,Brian Lian ,Body Weight Following ,Reported Adverse Events Following ,Viking Therapeutics ,Ligand Pharmaceuticals ,Nc ,